貝瑞基因(000710.SZ):子公司取得歐洲專利證書
格隆匯1月12日丨貝瑞基因(000710.SZ)公佈,公司的全資子公司北京貝瑞和康生物技術有限公司於近日獲得歐洲專利局頒發的專利證。專利名稱為一種用於檢測染色體拷貝數變異的測序文庫構建方法和試劑盒。
上述專利是公司產品“科諾安”的核心專利之一,本發明涉及用於檢測染色體拷貝數變異的測序文庫構建方法和試劑盒,本發明的目的在於克服傳統檢測染色體拷貝數變異的方法在分辨率、全基因組覆蓋程度、通量和成本等方面的不足,同時克服NGS建庫過程中PCR擴增偏好性帶來的問題,提供了一種不依賴PCR的檢測染色體拷貝數變異的測序文庫構建方法和試劑盒。採用該方法和試劑盒對待測樣本進行染色體拷貝數變異檢測,可實現對染色體非整倍體和染色體微缺失微重複綜合徵的篩查和診斷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.